yingweiwo

SHP2

SHP2

A 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP), Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2) is encoded by the PTPN11 gene. SHP2 participates in a number of signaling pathways, including PI3K-AKT, JAK-STAT, RAS-MAPK, and PD-1/PD-L1. Additionally, SHP2 controls mitochondrial homeostasis to negatively regulate the activation of the recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome. SHP2 has been viewed as a very desirable target for treating human diseases, particularly cancer.

SHP2 related products

Structure Cat No. Product Name CAS No. Product Description
3-Azetidinemethanol hydrochloride V69746 3-Azetidinemethanol hydrochloride 928038-44-2 3-Azetidinemethanol HCl is a pharmaceutical intermediate that may be utilized in the preparation /synthesis of SHP2 inhibitors.
Batoprotafib (TNO155) V2183 Batoprotafib (TNO-155) 1801765-04-7 TNO155 (TNO-155) is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11; IC50=11 nM) with potential anticancer activity.
BPDA2 V69753 BPDA2 2907659-86-1 BPDA2 is a selective and competitive active site SHP2 inhibitor, with IC50s of 92.0 nM, 33.39 μM, and 40.71 μM for SHP2, SHP1, and SHP1B respectively.
CNBCA V78677 CNBCA CNBCA is a specific, and competitive SHP2 enzyme inhibitor (antagonist) with IC50 of 0.87 μM.
NAT6-297775 V50955 NAT6-297775 1348433-02-2 SHP2 inhibitor
NSC-87877 V3210 NSC-87877 56990-57-9 NSC-87877 (NSC87877) is a novel, potent, cell-permeable small molecule and competitive inhibitor of SHP-1 and SHP-2 PTP (protein tyrosine phosphatase) with anticancer activity.
NSC-87877 disodium V51367 NSC-87877 disodium 56932-43-5 SHP-1 and SHP-2 PTP inhibitor
PB17-026-01 V85833 PB17-026-01
PF-03622905 V41014 PF-03622905 1072100-15-2 PF-03622905 is a potent ATP-competitive PKC inhibitor (antagonist) with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ and PKCθ, respectively.
PF-04577806 V41013 PF-04577806 1072100-81-2 PF-04577806 is a specific and ATP-competitive PKC inhibitor.
PF-07284892 (ARRY-558) V69742 PF-07284892 (ARRY-558) 2498597-94-5 PF-07284892 (ARRY-558) is a potent orally bioactive SHP2 inhibitor (antagonist) with IC50 of 21 nM.
RMC-0331 V50901 RMC-0331 2488788-52-7 RMC-0331 is a novel and orally active inhibitor of SOS1.
RMC-4550 V5027 RMC-4550 2172651-73-7 RMC-4550 (RMC4550) is a novel, potent, selective and allosteric inhibitor of SHP2 phosphatase with anticancer activity.
SHP099 V3045 SHP099 1801747-42-1 SHP099 (SHP-099), identified through HTS and structure-based drug design, is a potent, selective, orally bioavailable, and highly efficacious allosteric inhibitor of SHP2 [Src homology-2 domain containing protein tyrosine phosphatase-2] with anticancer and anti-osteoarthritis activity.
SHP099 HCl V3046 SHP099 HCl 1801747-11-4 SHP099 HCl, the HCl salt of SHP-099, isan orally bioavailable, and allostericSHP2 inhibitor with antitumor and anti-inflammatory effects.
SHP2-IN-13 V69762 SHP2-IN-13 2951854-02-5 SHP2-IN-13 is a selective and orally bioactive SHP2 “tunnel site” allosteric inhibitor (antagonist) with IC50 of 83.0 nM.
SHP2-IN-14 V69748 SHP2-IN-14 2673400-91-2 SHP2-IN-14 (compound 27) is an orally bioavailable allosteric inhibitor of SHP2 (IC50=7 nM) with anti-tumor activity.
SHP2-IN-16 V78898 SHP2-IN-16 SHP2-IN-16 (compound 222) is a SHP2 inhibitor (antagonist) with IC50 of 1 nM.
SHP2-IN-17 V69757 SHP2-IN-17 2941498-93-5 SHP2-IN-17 (compound 192) is a SHP2 inhibitor (antagonist) with IC50 of 2 nM.
SHP2-IN-18 V69759 SHP2-IN-18 2941498-87-7 SHP2-IN-18 (compound 183) is a SHP2 inhibitor (antagonist) with IC50 of 3 nM.
Contact Us